Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) and Qiagen (NYSE:QGEN – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.
Insider and Institutional Ownership
15.4% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 58.0% of Qiagen shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Finch Therapeutics Group and Qiagen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Finch Therapeutics Group | -25,084.36% | -115.37% | -64.42% |
| Qiagen | 17.04% | 13.72% | 7.54% |
Volatility and Risk
Analyst Recommendations
This is a breakdown of current ratings and price targets for Finch Therapeutics Group and Qiagen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Finch Therapeutics Group | 0 | 0 | 0 | 0 | N/A |
| Qiagen | 0 | 3 | 3 | 0 | 2.50 |
Finch Therapeutics Group presently has a consensus target price of $210.00, suggesting a potential upside of 3,502.06%. Qiagen has a consensus target price of $49.50, suggesting a potential upside of 23.41%. Given Finch Therapeutics Group’s higher probable upside, equities research analysts clearly believe Finch Therapeutics Group is more favorable than Qiagen.
Earnings & Valuation
This table compares Finch Therapeutics Group and Qiagen’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Finch Therapeutics Group | $860,000.00 | 10.85 | -$114.65 million | ($86.61) | -0.07 |
| Qiagen | $1.98 billion | 4.62 | $423.21 million | $1.47 | 27.29 |
Qiagen has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Summary
Qiagen beats Finch Therapeutics Group on 10 of the 13 factors compared between the two stocks.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
About Qiagen
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
